Diagnosis, Mimics, and Checklists
At a Glance
Lytico-Bodig has no single blood test or brain scan that confirms it during life. Doctors make a working diagnosis by combining movement, muscle, and thinking symptoms with the person’s history, neurological and cognitive exams, and tests such as MRI or EMG to rule out mimics.
Diagnosing Lytico-Bodig (ALS/PDC) is a complex process. Because there is no single validated antemortem biomarker (blood test or brain scan) that can prove someone has it while they are alive, clinicians make a working clinical diagnosis from the phenotype, history, and examination [1][2].
For a patient or caregiver, this process can feel like a long series of tests. Understanding the tools doctors use can help you advocate for a thorough evaluation.
Distinguishing Lytico-Bodig from its “Mimics”
Because Lytico-Bodig is a clinical spectrum, it often looks like several other neurological diseases. Doctors work to identify features that may help clinicians compare possibilities:
- Progressive Supranuclear Palsy (PSP): Like the “Bodig” form, PSP causes stiffness and frequent falls. However, PSP typically features a specific problem with vertical eye movements. A PSP-like clinical presentation should prompt careful differential diagnosis [3].
- Standard Parkinson’s Disease: While both involve stiffness and slow movement, “Bodig” symptoms typically do not respond as well to standard Parkinson’s medications like levodopa [2]. (However, levodopa response is not a reliable diagnostic separator because atypical parkinsonism can sometimes respond).
- Classic ALS: The “Lytico” form looks almost exactly like standard ALS. While standard ALS can include cognitive or behavioral impairment within the ALS-frontotemporal spectrum, Lytico-Bodig often includes severe parkinson-like stiffness [4][5].
- Alzheimer’s Disease: Memory loss in Lytico-Bodig can look like Alzheimer’s. However, the early addition of physical movement problems usually points toward the ALS/PDC spectrum, though late Alzheimer’s can also develop gait problems [4][6].
The Role of Technology in Diagnosis
While scans cannot “see” Lytico-Bodig directly, they provide important clues.
- MRI (Magnetic Resonance Imaging): Doctors use MRI primarily to rule out strokes, tumors, or other causes of dementia [3][7].
- EMG and Nerve Conduction Studies: If there is muscle weakness or twitching, an EMG (electromyogram) is used to check the health of the motor neurons [8][1].
- Eye Exams (LRPE): A historical research finding called linear retinal pigment epitheliopathy (LRPE) was associated with people with Lytico-Bodig [9]. However, its diagnostic value and specificity are not established for routine practice, so it is neither necessary nor sufficient for diagnosis [9].
A Checklist for a Complete Evaluation
An exhaustive checklist is not required for every patient, but a thorough diagnostic process should consider:
- Detailed History: A full review of time spent in Guam or the Western Pacific, any history of eating traditional foods, and a complete family history [10][4].
- Cognitive Testing: Formal “pen and paper” tests to measure memory, judgment, and behavior. These help distinguish this from other types of dementia [11][12].
- Physical/Neurological Exam: A check of eye movements, muscle strength, reflexes, and “parkinsonian” symptoms like tremors or stiffness [4][2].
- Swallow and Breathing Screen: Selected according to the person’s symptoms, early baseline tests of these functions are vital for safety [13].
- Medication Trial: A trial of levodopa is often used to see if movement symptoms improve [2].
- Genetic Counseling: Depending on family history, a doctor may recommend genetic counseling before any testing [14][3].
The Role of Neuropathology
Clinicians make a working diagnosis from history and testing; definitive neuropathologic confirmation is only possible through postmortem examination of the brain tissue (autopsy), which looks for tau and TDP-43 [6][15]. This is optional and not required for care, but many families find peace in having a definitive answer and contribute to research through brain donation programs [5].
Common questions in this guide
How is Lytico-Bodig diagnosed if there is no single test?
What conditions can look like Parkinson-dementia complex of Guam?
Can an MRI or EMG confirm Lytico-Bodig?
Does levodopa response distinguish Lytico-Bodig from Parkinson’s disease?
Is a retinal pigment epitheliopathy eye finding required for diagnosis?
Is a brain autopsy needed to care for someone with Lytico-Bodig?
Get notified when new evidence is published on Parkinson-dementia complex of Guam.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
[Parkinson-dementia and amyotrophic lateral sclerosis association (complex of Guam). Diagnostic challenge, Mexican patient].
Aguilar-Vázquez CA, Gallardo-González LI, Raymundo-Carrillo AD, et al.
Revista medica del Instituto Mexicano del Seguro Social 2023; (61(5)):677-684 doi:10.5281/zenodo.8316479.
PMID: 37773166 - 2
Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.
Quinn C, Elman L
Continuum (Minneapolis, Minn.) 2020; (26(5)):1323-1347 doi:10.1212/CON.0000000000000911.
PMID: 33003004 - 3
'Hummingbird' Sign in a Patient with Guam Parkinsonism-Dementia Complex.
Yeo T, Tan LC
Journal of movement disorders 2017; (10(3)):145-148 doi:10.14802/jmd.17025.
PMID: 28782342 - 4
Lytico-bodig in Guam: Historical links between diet and illness during and after Spanish colonization.
Giménez-Roldán S, Steele JC, Palmer VS, Spencer PS
Journal of the history of the neurosciences 2021; (30(4)):335-374 doi:10.1080/0964704X.2021.1885946.
PMID: 34197260 - 5
Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC.
Spencer PS
Journal of the neurological sciences 2022; (433()):120021 doi:10.1016/j.jns.2021.120021.
PMID: 34635325 - 6
Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam.
Verheijen BM, Oyanagi K, van Leeuwen FW
Frontiers in neurology 2018; (9()):173 doi:10.3389/fneur.2018.00173.
PMID: 29615966 - 7
Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study.
Calvo A, Chiò A, Pagani M, et al.
Journal of neurology 2019; (266(7)):1633-1642 doi:10.1007/s00415-019-09305-0.
PMID: 30949819 - 8
Brait-Fahn-Schwartz Disease: A Unique Co-Occurrence of Parkinson's Disease and Amyotrophic Lateral Sclerosis.
Aslam A, Sarmad E, Nawaz A, et al.
Case reports in neurology 2023; (15(1)):207-214 doi:10.1159/000532092.
PMID: 37901127 - 9
A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
Steele JC, Wresch R, Hanlon SD, et al.
Movement disorders : official journal of the Movement Disorder Society 2015; (30(9)):1271-5 doi:10.1002/mds.26264.
PMID: 26153661 - 10
Brain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin.
Spencer PS, Berntsson SG, Buguet A, et al.
Journal of the neurological sciences 2025; (468()):123340 doi:10.1016/j.jns.2024.123340.
PMID: 39667295 - 11
Clinical usefulness of scales for evaluating cognitive impairment in patients with amyotrophic lateral sclerosis.
Nagashima K, Makioka K, Fujita Y, et al.
Journal of the neurological sciences 2019; (405()):116414 doi:10.1016/j.jns.2019.07.032.
PMID: 31419623 - 12
Amyotrophic lateral sclerosis: a clinical review.
Masrori P, Van Damme P
European journal of neurology 2020; (27(10)):1918-1929 doi:10.1111/ene.14393.
PMID: 32526057 - 13
Providing life-sustaining treatments at home for those with Motor Neurone Disease: A qualitative study of bereaved family members' experiences of responsibility.
Wilson E, Palmer J, Kaltsakas G, et al.
Palliative medicine 2025; (39(5)):584-593 doi:10.1177/02692163251327866.
PMID: 40119769 - 14
Defining neurodegeneration on Guam by targeted genomic sequencing.
Steele JC, Guella I, Szu-Tu C, et al.
Annals of neurology 2015; (77(3)):458-68 doi:10.1002/ana.24346.
PMID: 25558820 - 15
Guam ALS-PDC is a distinct double-prion disorder featuring both tau and Aβ prions.
Condello C, Ayers JI, Dalgard CL, et al.
Proceedings of the National Academy of Sciences of the United States of America 2023; (120(13)):e2220984120 doi:10.1073/pnas.2220984120.
PMID: 36952379
This page explains how clinicians evaluate suspected Lytico-Bodig and compare it with similar neurological conditions for informational purposes only; it does not constitute medical advice. A neurologist should interpret your loved one’s symptoms and test results.